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Abstract: Medical treatment of emphysema does not alter the natural progression of the 
disease. Surgical techniques are an attractive conceptual approach to treat hyperinﬂ  ation in these 
patients. Lung volume reduction surgery and lung transplantation are appropriate therapeutic 
options for a selected population with emphysema. We will review the available evidence to 
support these approaches.
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Introduction
Emphysema is a progressive, debilitating disease characterized by an irreversible 
destruction of alveolar septa. Medical therapy undoubtedly provides symptomatic 
improvement, however, it does not alter the natural progression of the disease. 
As a consequence, chronic obstructive pulmonary disease (COPD) continues to 
be one of the leading causes or morbidity and mortality worldwide, and places a 
significant economic burden over individuals and society. In the United States, 
expenditures for Medicare beneficiaries with COPD are nearly 2.5 times higher 
than per capita total expenditures of those without COPD (US$8,482 vs US$3,511) 
(Sullivan et al 2000). Chronic lower respiratory diseases represented the fourth 
leading cause of death in the United States in 2005 (mortality rate was 44.2 per 
100,000 population), showing no significant variation within the last 5 years 
(Kung et al 2008).
Since altered respiratory mechanics play a pivotal role in the pathophysiology 
of emphysema, manipulation of the intervening structures by means of surgery 
have been seen as an attractive approach for several decades. The history of such 
approaches has been elegantly reviewed elsewhere (Deslauriers 1996). We will 
attempt to provide an evidence-based perspective to the current views on how to 
surgically manage emphysema, focusing on lung volume reduction surgery (LVRS), 
and lung transplantation. A PubMed search was conducted utilizing the terms 
“lung volume reduction surgery”, “lung transplantation”, and “chronic obstructive 
pulmonary disease”. Relevant publications were selected based on level of evidence; 
randomized controlled studies were preferred when available. Otherwise, the best 
available level of evidence literature was chosen. Emphasis was made on the last 
ten years, although studies that had historic relevance were also included. Although 
results may appear somewhat encouraging, this fact is shadowed by the fact that very 
few patients with emphysema are eligible for surgical treatment; this is particularly 
true for those with advanced and debilitating disease where medical treatment is 
clearly ineffective.International Journal of COPD 2008:3(4) 630
Mora and Hadjiliadis
Lung volume reduction surgery 
(LVRS) and lung physiology
Physiologically, emphysema is characterized by decreased 
elastic recoil, increased lung compliance, early airway 
closure, air trapping, overexpansion of the rib cage and 
ﬂ  attening of the diaphragm. Dynamic airway compression 
creates trapped areas within the lung parenchyma. This 
compression is more evident at high lung volumes, and 
becomes manifested in emphysema, producing increased 
thoracic gas volume. Spirometrically this is evidenced by 
decreased forced vital capacity (FVC) and forced expiratory 
volume in one second (FEV1), along with hyperinﬂ  ation.
When a portion of a hyperinﬂ  ated emphysematous lung is 
surgically removed, the remaining portion of the lung stretches 
within the thorax. An unchanged chest wall operating on a 
smaller lung restores the elastic recoil (Loring et al 1999), and 
expiratory ﬂ  ows at any given lung volume increase on the 
basis of increased airway traction and delayed airway closure. 
LVRS translates into reduced thoracic gas compression by 
improving expiratory ﬂ  ow limitation: FEV1 is consistently 
improved, and both total lung capacity (TLC) and residual 
volume (RV) are reduced. (Sharafkhaneh et al 2005) Dia-
phragmatic muscle ﬁ  ber length and geometry is also optimized 
(Gorman et al 2005), likely decreasing respiratory effort, and 
producing a theoretical improvement in dyspnea.
Oxygen consumption and resting energy expenditure are 
increased in emphysema because of impaired respiratory 
mechanics, with greater oxygen cost of breathing and 
substrate oxidation that favors lipid catabolism. Lung volume 
reduction surgery signiﬁ  cantly decreases proportional oxygen 
consumption of respiratory muscles and resting energy 
expenditure over respiratory rehabilitation. Correlations with 
residual volume and nutritional status suggest that restoration 
of respiratory mechanics reduces energy expenditure and 
approximates metabolism to normal (Mineo et al 2006).
Disruption of the lung parenchyma, as seen in emphysema, 
adversely affects cardiovascular function. Pulmonary 
endothelial dysfunction (Fira-Mladinescu et al 2007), 
persistent hypoxemia and decreased cross-sectional area 
of the pulmonary system translates in increased pulmonary 
vascular resistance and increased right ventricular afterload. 
Overtime, the right ventricle will remodel and may 
compromise left ventricular ﬁ  lling and function by altering 
interventricular septal geometry. Conceptually, a therapeutic 
intervention able to improve gas exchange, and improve 
ventilation-perfusion matching, would ameliorate the 
deleterious hemodynamic consequences of emphysema. 
Although LVRS may accomplish this purpose, removal 
of lung parenchyma also removes lung vasculature, and 
necessarily produces physical deformation of lung vessels. 
It appears LVRS does not produce a signiﬁ  cant difference 
in pulmonary artery pressures as measured six months after 
the procedure (Criner et al 2007).
LVRS: Surgical techniques
The ﬁ  rst physiology-oriented surgical approach to manage 
emphysema dates back to the 1950’s when Brantigan 
hypothesized that surgical reduction of lung volumes would 
translate in restoring of radial traction. Surgical techniques 
have varied over the years. Commonly utilized approaches 
include median sterenotomy (MS), standard thoracotomy, 
and video assisted thoracic surgery (VATS) (Martinez and 
Chang 2005). The use of a less invasive approach such as 
VATS seems to translate in reduced postoperative cytokine 
release, and hence, reduced postoperative infections and 
mechanical ventilation times (Frisca et al 2007). Although 
no deﬁ  nitive consensus exists, improvement seems to be 
greater with bilateral procedures regardless of the approach 
(Ocy el al 2002).
Bronchoscopic novel techniques, where airways leading 
to hyperinﬂ  ated lung segments are instrumentally obstructed 
leading to distal collapse and reduced hyperinﬂ  ation seem 
promising based on published case series (Hopkison 2007). 
Unilateral procedures seem to produce better physiologic 
outcomes. Which patients beneﬁ  t the most and selection 
criteria are still to be determined (Wan et al 2006).
NETT
The assumption that physiologic improvements would 
translate in symptomatic improvement and may alter the 
natural history of emphysema served as the basis for LVRS 
as a therapeutic option for emphysema. Isolated short case 
series and small randomized trials suggested that selected 
patients might beneﬁ  t from LVRS showing improvements 
in expiratory ﬂ  ow, exercise capacity and quality of life. The 
Washington University group showed a 90-day mortality 
rate of 4%, with modest postoperative complications 
(Cooper et al 1996). Other series reported comparable 
low rates of initial procedure- inherent complications and 
early physiologic improvement – improved FEV1, reduced 
TLC and RV, and improvement in six-minute walk dis-
tance (6MWD) test (Criner et al 1999; Pompeo et al 2000; 
Geddes et al 2000). Not surprisingly for a procedure being 
initially offered as palliative, quality of life assessments 
were also positive (Ciccone et al 2003). These encourag-
ing results were not as impressive in Medicare-based data. International Journal of COPD 2008:3(4) 631
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Early 30-day postoperative mortality was reported to be as 
high as 23% (DHHS 1998); poor preoperative patient selec-
tion was probably a major determinant of these outcomes. 
Aside from the fact that these trials were arguably method-
ologically ﬂ  awed, none of them showed an effect on mortality 
(Lederer and Aracsoy 2007).
When one systematically reviews the literature it becomes 
obvious that perhaps the strongest evidence to date comes 
from the National Emphysema Treatment Trial (NETT) 
(Fishman et al 2003). A large, prospective, randomized, 
multicenter, long-term study, the NETT compared optimal 
medical care to bilateral LVRS using median sternotomy 
(70%) or VATS (30%), added to medical therapy. The 
results of this trial were published in 2003 after a median 
two-and-a-half year follow-up, and again in 2006 after a 
median approximate four-year follow-up (Naunheim et al 
2006). The 90-day mortality rate was signiﬁ  cantly higher 
in the surgical group (7.9% vs 1.3% in the medical group, 
p   0.001); this difference was not related to the surgical 
technique chosen. Despite this early mortality in the surgical 
group (the “pay-up-front” effect), there was no signiﬁ  cant 
difference overall mortality between the two groups (Fishman 
et al 2003). However, there was a 6.6% absolute mortality 
reduction in the LVRS arm in the extended follow-up report 
(Naunheim et al 2006). As suggested by studies predating 
the NETT trial (Flaherty and Martinez 2000), LVRS had a 
positive physiologic impact. Exercise capacity improvement 
was signiﬁ  cantly higher in the surgical over the 24-month 
follow-up period, as demonstrated by improved 6MWD, and 
predicted FEV1 percentage. Health-related quality of life and 
dyspnea also improved signiﬁ  cantly more in the surgical 
group (Fishman et al 2003).
The presence of homogenous emphysema or preoperative 
carbon monoxide diffusing capacity of 20% or less of 
predicted, along with an FEV1 of 20% or less of predicted, 
were clearly associated with a high-risk of death after LVRS 
and minimal functional beneﬁ  t as identiﬁ  ed early in the 
NETT trial; within 30 days following surgery the mortality on 
this group was as high as 16%, and after 6 month 33% have 
died (Fishman et al 2001). This high-risk group of patients 
is clearly unsuitable for LVRS.
A post hoc analysis identified a subgroup that may 
potentially beneﬁ  t from LVRS (Fishman et al 2003), and 
more importantly, it was a able to identify a subgroup of 
patients in whom LVRS may be detrimental. The craniocaudal 
distribution of emphysema and the base-line exercise capacity 
were showed to be predictive of LVRS beneﬁ  t. Patients with 
predominantly upper-lobe emphysema and low exercise 
capacity preoperatively beneﬁ  ted from LVRS: they showed 
signiﬁ  cantly lower mortality, improved exercise capacity and 
improvement in standardized symptom scores as compared 
with the medical-therapy group. On the other hand, in patients 
with non-upper lobe disease and high exercise capacity, 
LVRS translated in a higher risk of death. The risk of death 
was not signiﬁ  cantly modiﬁ  ed by surgery in other groups with 
different anatomical distribution of emphysema and exercise 
capacity combinations (Fishman et al 2003).
Genetic determinants of emphysema 
distributions in the NETT trial
The NETT genetics ancillary study involved a cohort of 
282 patients in whom tomographic emphysema phenotypes 
were correlated with genetic polymorphisms for association 
with emphysema distribution. Polymorphisms in the 
xenobiotic metabolizing enzymes GSTP1 and EPHX1 are 
associated tomographic apical-predominant emphysema 
(DeMeo et al 2007). Furthermore, the presence of these 
enzymatic genotypes predicted a better response to LVRS, 
as evidenced by reduction in BODE score; this improvement 
was more signiﬁ  cant in the patients with low exercise capacity 
(Hersh et al 2007). Genetic characterization of emphysema 
may well be a screening tool in the future allowing to 
determine those patients that may beneﬁ  t from LVRS.
Alpha-1 antitrypsin deﬁ  ciency 
and LVRS
Alpha-1 antitrypsin (AAT) deﬁ  ciency patients have been 
excluded from most LVRS trials. However, 10 of the subjects 
randomized in the NETT trial had severe AAT deﬁ  ciency. 
When outcomes were compared between AAT-deﬁ  cient 
patients undergoing LVRS and those with normal levels, 
deﬁ  cient individuals had a shorter duration in FEV1 rise, 
smaller increase in exercise capacity at 6 months, and higher 
mortality. Although these conclusions are inherently limited 
by the small number of patients analyzed, LVRS cannot 
clearly be recommended for this population based on the 
above data (Stoller et al 2007). In addition, most patients with 
AAT deﬁ  ciency have lower lobe predominant emphysema, 
which showed the least surgical beneﬁ  t in NETT (leading to 
worse outcomes in good exercise capacity patients).
Effect of LVRS on COPD exacerbations
The efficacy of traditional bronchodilator and anti-
inflammatory therapy to prevent COPD exacerbations 
continues to be a debatable subject. Although prospective International Journal of COPD 2008:3(4) 632
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analysis of the effect of LVRS on COPD exacerbation was 
not one of the end-points of the NETT trial, a recent post-hoc 
analysis based on medical claims data on patients who took 
part on the NETT trial shows a signiﬁ  cant reduction in the 
frequency of exacerbations (30%, P = 0.00005) in the surgical 
cohort; this difference is even more marked in those patients in 
whom surgery produced larger FEV1 improvements. The time 
to the ﬁ  rst exacerbation was also better for the surgical group 
(Washko et al 2008). These correlations, although attractive, 
do not necessarily mean that LVRS reduces COPD exacerba-
tions. It is possible that the improved baseline perception of 
dyspnea achieved by the LVRS group translates in a reduced 
frequency of emergent care, and a consequent reduction in 
reported claims.
Cost-effectiveness (CE) of LVRS
In parallel to the NETT trial, a prospective, economic analysis 
was performed (Ramsey et al 2003) showing a cost of 
US$190,000 per quality-adjusted life year (QALY) for LVRS 
compared to optimal medical care after a three-year follow-up 
period. Based on extrapolation models, it was forecasted 
that after ten years this amount would be US$21,000 for the 
group that showed the most beneﬁ  t after LVRS, ie, upper 
lobe, low exercise capacity. This determination translated 
in Medicare covering for the procedure in all groups of the 
NETT trial with the exception of those with non-upper-lobe 
disease and high exercise capacity. A recent report (Ramsey 
et al 2007) based on an actual 5- to 10-year follow-up of the 
NETT cohort showed that the above extrapolations greatly 
overestimated the cost-effectiveness of LVRS. The actual 
CE was $48,000 per QALY at 10 years in the upper lobe, 
low exercise capacity group. However, this fact is unlikely 
to change the way Medicare reimburses for LVRS, given the 
supportive clinical evidence.
Lung transplantation for COPD
In 2005, the worldwide number of lung transplantations 
reached approximately 2100. Two thirds of these operations 
are done in the United States (Pierson et al 2004; Trulock 
et al 2005). The first lung transplant for COPD in the 
modern era was performed in 1986. Since then COPD has 
become the most common indication for lung transplantation 
(Trulock et al 2005) accounting for 45.9% of all lung 
transplants (38.0% emphysema and 7.9% alpha-1-antitrypsin 
deficiency). These ratios have changed in the United 
States since the implementation of the new lung allocation 
system in May 2005. As a result in 2005 COPD accounted 
for only 31.4% of transplants in the United States and 
alpha-1-antitrypsin deﬁ  ciency accounted for 3.6%. These 
numbers decreased further in the United States in 2006 to 
30.1% and to 3.2% respectively (OPTN 2008). However, 
COPD and alpha-1-antitrypsin deficiency remain the 
most common diagnoses for which lung transplantation 
is performed (OPTN 2008). For the rest of this review 
the term COPD will be used to describe both COPD and 
alpha-1-antitrypsin deﬁ  ciency unless otherwise speciﬁ  ed.
After early fears that single lung transplantation (SLT) 
would not be feasible because of native lung hyperinﬂ  ation 
(Venuta et al 1999), it became obvious that both SLT and 
bilateral lung transplantation (BLT) offer good options for 
patients with COPD (Pochetino et al 2000). They both offer 
similar short-term outcomes (Pochettino et al 2000), but BLT 
appears to provide superior long-term outcomes (Meyer et al 
2001; Cassivi et al 2002; Hadjiliadis et al 2006). On the other 
hand SLT offers transplant to two patients, rather than one 
and it can potentially reduce waiting list times (Hadjiliadis 
et al 2006b). In recent years percentage of BLT transplants 
for COPD has increased (Trulock et al 2007). However, no 
randomized trials have evaluated the relative merits of each 
operation and there are inherent biases (local and national) 
while selecting BLT vs SLT for a speciﬁ  c patient. Therefore 
the best operation for each patient should be selected on an 
individual basis.
Unfortunately, no studies have demonstrated a consistent 
transplantation survival advantage for this group of patients 
when analyzed as a whole (grouping SLT and BLT recipients) 
post-transplantation. A large review using data from the US 
registry suggested that lung transplantation for COPD did 
not prolong survival (Hosenpud et al 1998). However, two 
smaller European studies suggest that lung transplantation 
for COPD did improve survival, albeit to a lesser extent 
when compared to other diagnoses (De Meester et el 2001; 
Charman et al 2002). The disparity between these studies may 
come from the fact that the European centers involved used 
a severity of illness allocation system, while those centers in 
the US registry utilized waiting time to allocate organs under 
the prior allocation system. No study has examined whether 
lung transplantation offers a potential survival advantage for 
patients with COPD after the implementation of the new Lung 
Allocation Score in the United States, which offers lungs 
based waiting list urgency and transplant beneﬁ  t.
Lung transplantation selection 
criteria for patients with COPD
In general, patients referred for lung transplantation have to 
suffer from severe disease that cannot be medically managed International Journal of COPD 2008:3(4) 633
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(Orens et al 2006). Unlike LVRS, transplantation can be 
offered to patients who have more severe disease and in fact 
it is geared towards that group (Patel et al 2008). In addition, 
patients have to be free of other signiﬁ  cant medical comor-
bidities, including heart disease, liver disease or renal failure 
(Orens et al 2006). They also need to have no signiﬁ  cant 
psychiatric illness and adequate ﬁ  nancial and psychosocial 
support (Orens et al 2006). Absolute contraindications to lung 
transplantation include any of the above-mentioned medical 
comorbidities and uncontrolled or untreatable infection (Orens 
et al 2006); recent cancer (Orens et al 2006). Relative contrain-
dications include active hepatitis C without cirrhosis, medically 
or surgically treated coronary disease, prior thoracic surgery 
(especially with pleurodesis and/or chest wall deformity), acute 
critical illness, advanced age (most programs consider 65 years 
the upper age limit for lung transplantation), poor nutritional 
status (over or underweight) and physical debilitation (Orens 
et al 2006). Lung transplant centers differ on their philosophy 
of accepting high-risk candidates and what contraindications 
they consider more important on the selection process.
Speciﬁ  c selection criteria for referral for transplant for 
patients with COPD include patients with FEV1   25%, 
BODE index of 5 or higher (Orens et al 2006). Timing of 
actual listing for lung transplantation is reserved for patients 
with acute hypercapnea in the setting of hospitalization, 
pulmonary hypertension or cor pulmonale in the setting of ade-
quate oxygen therapy, BODE index of 7 or higher and FEV1 of 
less than 20% with DLCO of less than 20% or homogeneous 
distribution of emphysema (Orens et al 2006).
Survival of lung transplant 
recipients with COPD
Survival after lung transplantation has improved over the 
last few years, however it remains limited. One year, 3-year, 
5-year and 10-year survival for patients receiving BLT vs SLT 
are 83.8% vs 80.5%, 67.8% vs 62.5%, 56.3% vs 46.5% and 
30.1% vs 17.7%, respectively (p   0.001) (Trulock et al 2007). 
However, SLT recipients tend to be older and have more 
comorbidities in most centers, so these results are difﬁ  cult to 
assess with respect to the merit of each operation (Meyer et al 
2001; Cassivi et al 2002; Hadjiliadis et al 2006). From the 
survival statistics it is obvious that only patients with the most 
severe disease are likely to beneﬁ  t from this procedure.
Physiologic outcomes after lung 
transplantation
Lung transplantation dramatically improves most physiologic 
parameters of patients with COPD. FEV1 and FVC improve, 
while TLC and RV tend to normalize; in addition, need for 
oxygen disappears and carbon dioxide normalizes. Six-minute 
walk distance improves dramatically too (Levine et al 1994; 
Sundaresan et al 1996; Bavaria et al 1997; Pochettino et al 
2000; Cassivi et al 2002). The improvements seen after lung 
transplantation are more dramatic compared with LVRS 
although no study has made a head to head comparison of 
similar group of patients. Studies have compared the two 
procedures and they have showed increased mortality with 
transplant; however, in all studies transplant was reserved 
for patients with more advanced COPD (Weinstein et al 
1997; Meyers et al 2001). When patients receiving BLT 
are compared with SLT recipients all parameters tend to be 
better in the BLT group, although even SLT recipients have 
very signiﬁ  cant improvements in all parameters (Levine et al 
1994; Sundaresan et al 1996; Bavaria et al 1997).
Quality of life after lung 
transplantation
Quality of life signiﬁ  cantly improves after lung transplantation 
for COPD. No prospective trial has assessed the same group 
of patients before and after transplant in a longitudinal 
fashion. However the changes in cross sectional studies are 
highly signiﬁ  cant (Anyawu et al 2001; Gerbase et al 2005). In 
another study, utilizing the survival analysis from the patient 
with Hosenpud, showed that despite a possibly worse survival 
in patients with COPD after lung transplantation, their quality 
of life-adjusted years were better after lung transplantation 
(Singer et al 2002).
Complications after lung 
transplantation
There are many complications after lung transplantation 
that contribute to its high mortality. Patients after lung 
transplantation have to take multiple medications, including 
three immunosuppressive agents in most cases (calcineurin 
inhibitor: cyclosporine or tacrolimus; cell cycle inhibitor: 
azathioprine or mycophenolate mofetil; prednisone) (Arcasoy 
and Kotloff 1999; Trulock et al 2007). Despite the heavy 
immunosuppression, acute rejection occurs frequently 
after lung transplantation and it frequently requires high 
doses of steroids for treatment. In addition, many patients 
develop obliterative bronchiolitis (chronic rejection) by 
5 years after lung transplantation (Arcasoy and Kotloff 1999; 
Trulock et al 2007). The immunosuppressive regimen makes 
patients susceptible to infections, including aspergillus, 
cytomegalovirus, and other respiratory viruses, and they 
constitute the second leading cause of death among lung International Journal of COPD 2008:3(4) 634
Mora and Hadjiliadis
transplant recipients (Arcasoy and Kotloff 1999; Trulock 
et al 2007). The medications also lead to increased risk 
of hypertension, hyperlipidemia and diabetes mellitus 
(Arcasoy et al 2007). As a result, many patients also develop 
progressive renal failure, as the cumulative exposure to 
calcineurin inhibitors increases (Arcasoy et al 2007). Another 
signiﬁ  cant complication is an increased risk of cancer and 
greater difﬁ  culty in treating it (Arcasoy et al 2007). This 
is particularly true for patients receiving SLT that develop 
native lung cancer (Mac Adams et al 2001). In addition, all 
lung transplant recipients are at risk for post-transplant lym-
phoproliferative disorder (especially if they are Epstein–Barr 
virus-negative) (Arcasoy and Kotloff 1999; Trulock et al 
2007). There are other less common complications that will 
not be discussed further.
Conclusions
LVRS and lung transplantation offer appropriate options 
for patients with advanced COPD; no head-to-head trials 
have been performed, so the superiority of either one cannot 
be evaluated. Both lead to signiﬁ  cant improvements in 
physiologic and quality of life outcomes. However, LVRS 
leads to smaller improvements, but with fewer potential side 
effects than transplantation. On the other hand, transplantation 
offers the most dramatic beneﬁ  t. LVRS is usually appropriate 
for healthier patients and is not a contraindication for future 
lung transplantation. In general, patients eligible for the 
criteria described in the NETT trial should be offered that 
ﬁ  rst. However, the decision should be individualized based 
on patient preferences, center expertise and potential risk 
and beneﬁ  t of each procedure.
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